

ETHICON Plus Antibacterial Sutures



UK case story

Data collected from a National Health Service England (NHSE) Trust over 12 month period in 15 surgical specialties

Number of patients treated using Plus Antibacterial Sutures
5,086^{1,3}

Statistically significant SSI reduction
25.7%^{4, i, ii}

66^{4, iii}
SSIs avoided

Estimated savings from reduced SSI rate:

£206,109^{4, 5, iv}

Use of ETHICON Plus Antibacterial Sutures funded by the Innovation and Technology Payment (ITP) to support a reduction in Surgical Site Infection (SSI) within a National Health Service England (NHSE) Trust.

Always **EXPECT MORE** from Ethicon.

**EXPECT
MORE**
Plus is minus



ETHICON
PART OF THE **Johnson & Johnson** FAMILY OF COMPANIES

ⁱ Eligible specialties: Bariatric, Breast Augmentation, Breast Reconstruction, CABG, Cardiac, Colorectal, General Surgery, Gynaecology, Hernia, HPB, Hysterectomy, Oncological Ablations, Thoracic, UGI, Urology. ⁱⁱ Based on a Chi-square test; p value = 0.0016. Calculated using the total number of procedures in eligible specialties and the number of surgical site infections recorded in the implementation period and compared to the agreed SSI rate, procedure number and surgical site infections in the baseline period as defined in the ITP contract. ⁱⁱⁱ Based on the relative risk reduction of SSI with Plus Antibacterial Sutures in the subject NHS trust (25.74%), the SSI rate in the subject NHS trust with Plus Antibacterial Sutures (3.79%) and the number of patients during July 18 - June 19 (5086). ^{iv} Number of surgical site infections AVOIDED in eligible specialties multiplied by £3122.86 - NICE's estimation of the average cost of managing a single patient with an SSI. Case results may vary depending on clinical practice, workflow, and individual patient factors. These are commercial programs and are in no way a direct indicator of individual patient results. The Programs in the following case stories are NOT clinical investigations and there is no patient follow-up required. Consequently, the presented data cannot be considered as a measure of clinical outcome, nor does it imply any safety or performance claim relating to a medical device. The following data is provided as examples and have not been re-assessed with more recent data.

1. ETHICON, 20190601 - SSI Report 201906 SECTION 1, June 2019. Data on File. 2. ETHICON, 20190601 - SSI Report 201906 SECTION 2, June 2019. Data on File. 3. ETHICON, 20190601 - SSI Report 201906 SECTION 3, June 2019. Data on File. 4. ETHICON, 20200401 - NHS SSI Analysis, April 2020. Data on File. 5. NICE Guidelines. Surgical site infection: prevention and treatment. [D] Evidence review for the effectiveness of closure materials and techniques in the prevention of surgical site infection. NICE guideline NG125. Evidence reviews - April 2019. Available from <https://www.nice.org.uk/guidance/ng125/evidence/closure-materials-and-techniques-in-the-prevention-of-surgical-siteinfection-pdf-6727104401.66141660564421>. Accessed 6TH February, 2021.